Immunome IMNM Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -3,228.8%+154pp | -3,382.4%-2,601pp | -781.4%— | —— | |
| Net margin | -3,060%+180pp | -3,240.4%-2,478pp | -761.9%— | —— | |
| EBITDA margin | -3,193.3%+172pp | -3,365%-2,587pp | -778.1%— | —— | |
| Free cash flow margin | -2,890.1%-1,585pp | -1,304.8%— | —— | —— | |
| Returns | |||||
| Return on equity | -52.1%+143pp | -194.6%-38.2pp | -156.5%-42.6pp | -113.8%-58.6pp | |
| Return on assets | -46%+105pp | -150.7%-26.9pp | -123.8%-33.7pp | -90%-41.8pp | |
| Efficiency | |||||
| Asset turnover | 0×0.0× | 0×-0.1× | 0.2×— | —— | |
| Liquidity | |||||
| Current ratio | 14.7×+10.6× | 4.1×-2.6× | 6.6×+3.5× | 3.1×-2.7× | |
| Quick ratio | 14.7×+10.6× | 4.1×-2.6× | 6.6×+3.5× | 3.1×-2.7× | |
| Cash ratio | 14.5×+11.9× | 2.6×-1.9× | 4.5×+1.7× | 2.8×-2.3× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×— | —— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×— | —— | |
| Per Share | |||||
| Book value per share | $7.26+135% | $3.09-48.9% | $6.04+340% | $1.37-67.1% | |
| Valuation | |||||
| Market capitalization | $2.37B+258% | $662.87M+45.0% | $457.21M+1,606% | $26.8M-82.9% | |
| Enterprise value | $1.72B+228% | $524.35M+45.6% | $360.18M— | —— | |
| Price / sales | 341.4×+268× | 73.3×+40.7× | 32.6×— | —— | |
| Price / book | 3.7×+0.1× | 3.7×-0.2× | 3.8×+2.2× | 1.6×-1.6× | |
| EV / sales | 247.9×+190× | 58×+32.3× | 25.7×— | —— | |
| Free cash flow yield | -8.5%+9.3pp | -17.8%— | —— | -108%-96.3pp | |
| Earnings yield | -9%+35.2pp | -44.2%-20.8pp | -23.4%+114pp | -137.6%-122pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Immunome's ratios come from?
- Every ratio is computed from Immunome's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.